On March 10, 2022 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that multiple abstracts were selected for oral and poster presentations at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer to be held on March 18-21, 2022 in Phoenix, Arizona (Press release, ImmunoGen, MAR 10, 2022, View Source [SID1234609895]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ORAL PRESENTATION
Full results from the pivotal SORAYA trial of mirvetuximab soravtansine (mirvetuximab) in ovarian cancer will be shared in a late-breaking oral presentation.
Title: Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study
Presenter: Dr. Ursula Matulonis, Chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute, Professor of Medicine at the Harvard Medical School, and SORAYA Co-Principal Investigator
Session: Scientific Plenary IV: Late-Breaking Abstracts
Session Date: Saturday, March 19, 2022
Session Time: 4:15 pm to 5:45 pm MST
POSTER PRESENTATIONS
Trial in progress posters from ImmunoGen’s MIRASOL and PICCOLO trials of mirvetuximab in ovarian cancer and a Phase 2 investigator-sponsored combination trial of mirvetuximab with carboplatin in the neoadjuvant setting will also be presented.
Title: MIRASOL: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Presenter: Dr. Kathleen Moore, Director of the Oklahoma TSET Phase I Program, Associate Professor of the Section of Gynecologic Oncology at The University of Oklahoma College of Medicine, and MIRASOL Principal Investigator
Title: PICCOLO: An Open-Label, Single Arm, Phase 2 Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Presenter: Dr. Angeles Alvarez Secord, Professor of Obstetrics and Gynecology at Duke University School of Medicine in Durham, North Carolina
Title: Single-Arm Phase II Trial of Carboplatin and Mirvetuximab Soravtansine as Neoadjuvant Chemotherapy for Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer who are Folate Receptor α Positive
Presenter: Dr. Jhalak Dholakia, Department of Obstetrics and Gynecology at the University of Alabama
OTHER PRESENTATIONS
Final data from the mirvetuximab plus bevacizumab platinum-agnostic combination study, which were originally shared at ASCO (Free ASCO Whitepaper) 2021, will be re-presented.
Title: Mirvetuximab Soravtansine, a Folate Receptor Alpha-Targeting Antibody Drug Conjugate in Combination with Bevacizumab in Patients with Platinum-Agnostic Ovarian Cancer: Final Analysis
Session: Seminal Abstracts: The Best of ASCO (Free ASCO Whitepaper), ESMO (Free ESMO Whitepaper), IGCS, and ESGO
Presenter: Dr. David O’Malley, Professor, Director of Gynecologic Oncology and the Director of the Division of Gynecologic Oncology at The Ohio State University and the James Cancer Center
Additional information can be found on the SGO website.
INVESTOR EVENT INFORMATION
ImmunoGen will hold an investor event to discuss the SORAYA data, featuring a roundtable with key opinion leaders, on Sunday, March 20 at 7:30 am MST/10:30 am EDT in the Moly Meeting Room at the Westin Phoenix Downtown. To access the live event by phone, dial (877) 621-5803; the conference ID is 1986619. The event may also be accessed via webstream on the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.